Consano Bio
Burlington, US · Founded 2022 · Delaware corporation
Find your way into Consano Bio
196 people in our graph share verified history with the Consano Bio team — schools, employers, funds. One of them is your warm intro.
Noubar Afeyanunlockedknows Jennifer Schmitke · together at Omega Therapeutics (overlapped)
×8knows the team · via RMIT University
×2knows the team · via University of Melbourne
knows the team · via Magenta Therapeutics
Founders & leadership
AH
Andrew HallinChief Executive OfficerHe has held executive leadership roles focused on product commercialization, business development, and market strategy across therapeutic areas including immunology, oncology, and women's health.
JS
Jennifer SchmitkeinChief Operating Officer, Head of R&DShe brings experience from early-stage startups through large biotech organizations, with expertise in chemistry, manufacturing, and controls, as well as portfolio strategy.
DH
WS
WAYNE SCHELLHAMMERNamed on SEC filing
CH
CLAYTON HARTMANNamed on SEC filing
Board
BA
Bill AbbingtonBoard director
JA
Jerome AdamsBoard director
DV
Doug Vander WeideBoard director
CC
Chris CentenoBoard director
Reported raises · per SEC filings
Form D private placements$59.6M disclosed across 3 rounds · 2023–2026
▶$34.8MraisedMar 2026 · 28 investors · BiotechnologyRule 506(b)
▶$34.8MraisedMar 2026 · 28 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael PedeDirector
- Bill AbbingtonDirector
- John ConwayDirector
- Joe SchieslDirector
- Jennifer SchmitkeExecutive Officer
- Christopher CentenoDirector
- Doug Vander WeideDirector
- Andrew HallExecutive Officer, Director
- Jerome AdamsDirector
- Offering amount
- $48.9M
- Amount sold
- $34.8M
- First sale
- Mar 2026
- Incorporated
- Corporation, Delaware, 2024
- Federal exemptions
- 06b
▶$16.8MraisedDec 2025 · 18 investors · BiotechnologyRule 506(b)
▶$16.8MraisedDec 2025 · 18 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Bill AbbingtonDirector
- Jerome AdamsDirector
- Doug Vander WeideDirector
- Chris CentenoDirector
- Andrew HallExecutive Officer, Director
- Jennifer SchmitkeExecutive Officer
- Offering amount
- $16.8M
- Amount sold
- $16.8M
- First sale
- Oct 2024
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
▶$7.9MraisedJun 2023 · 1 investors · BiotechnologyRule 506(b)
▶$7.9MraisedJun 2023 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- DANIEL HADERSDirector
- WAYNE SCHELLHAMMERExecutive Officer, Director
- CLAYTON HARTMANDirector
- NA REGENEXX HOLDINGS, LLCExecutive Officer
- Offering amount
- $12M
- Amount sold
- $7.9M
- Minimum investment
- $100K
- First sale
- Jun 2023
- Incorporated
- Limited Liability Company, Delaware, 2022
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
FDA Grants Fast Track Status to Consano Bio’s Chronic Sciatica Drug - Pharma Journalistpharmajournalist.com · Aug 2026Frequently asked questions
- How much funding has Consano Bio raised?
- Consano Bio has disclosed $59.6M raised across 3 rounds.
- Where is Consano Bio headquartered?
- Consano Bio is headquartered in Burlington, US.